Larry Riedel
Internal Medicine · Victoria, TXNPI 1053373738
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $869 and has fallen 78.6% since, to $186 in 2023.
Across 89 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$176
- AstraZeneca$168
- Novartis$147
- Bayer$128
- Novo Nordisk$110
- Pfizer$110
- plus $741 from 17 others
What the payments were for
- Food & beverage$1,579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $176 |
| AstraZeneca | 9 | $168 |
| Novartis | 8 | $147 |
| Bayer | 6 | $128 |
| Novo Nordisk | 6 | $110 |
| Pfizer | 5 | $110 |
| Amgen | 6 | $95 |
| Merck | 6 | $94 |
| Astellas Pharma US Inc | 5 | $74 |
| Johnson & Johnson | 4 | $69 |
| Amarin Pharma, Inc. | 4 | $69 |
| UCB, Inc. | 2 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $53 |
| Dexcom, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $34 |
| Abbott | 1 | $25 |
| Lundbeck LLC | 1 | $21 |
| Biogen | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| GSK | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$1,579 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 32 | $234 |
| Amlodipine Besylate | 22 | $173 |
| Olmesartan Medoxomil | 11 | $104 |
| Metformin Hcl | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Victoria
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.